Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone

被引：30

作者：

Cho, Kyu Yong ^{[1
,2
,3
]}

Nakamura, Akinobu ^{[1
,2
]}

Omori, Kazuno ^{[1
,2
]}

Takase, Takahiro ^{[1
,2
]}

Miya, Aika ^{[1
,2
]}

Yamamoto, Kohei ^{[1
,2
]}

Nomoto, Hiroshi ^{[1
,2
]}

Kameda, Hiraku ^{[1
,2
]}

Taneda, Shinji ^{[4
]}

Kurihara, Yoshio ^{[5
]}

Aoki, Shin ^{[6
]}

Atsumi, Tatsuya ^{[1
,2
]}

Miyoshi, Hideaki ^{[1
,2
,7
]}

机构：

[1] Hokkaido Univ, Fac Med, Dept Rheumatol Endocrinol & Nephrol, Sapporo, Hokkaido, Japan

[2] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan

[3] Hokkaido Univ Hosp, Clin Res & Med Innovat Ctr, Sapporo, Hokkaido, Japan

[4] Manda Mem Hosp, Diabet Ctr, Sapporo, Hokkaido, Japan

[5] Kurihara Clin, Sapporo, Hokkaido, Japan

[6] Aoki Clin, Sapporo, Hokkaido, Japan

[7] Hokkaido Univ, Fac Med, Div Diabet & Obes, Sapporo, Hokkaido, Japan

来源：

JOURNAL OF DIABETES INVESTIGATION | 2021年 / 12卷 / 07期

关键词：

Fatty liver; Sodium– glucose cotransporter  2; inhibitor; Type  diabetes; TYPE-2; DIABETES-MELLITUS; HEPATIC STEATOSIS; JAPANESE PATIENTS; CANAGLIFLOZIN; IPRAGLIFLOZIN; ADIPONECTIN; FIBROSIS; PLACEBO; INDEX;

D O I：

10.1111/jdi.13457

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aims/Introduction Sodium-glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non-inferiority compared with pioglitazone for glycemic control, and superiority regarding weight reduction in patients with type 2 diabetes. We carried out a secondary analysis for the favorable effects of sodium-glucose cotransporter inhibitors for NAFLD. Materials and Methods In this multicenter, open-label, prospective, randomized, parallel-group comparison trial, patients taking pioglitazone for >= 12 weeks were randomly switched to dapagliflozin or continued pioglitazone for a further 24 weeks. The fatty liver index (FLI), consisting of body mass index, triglycerides, waist circumference and gamma-glutamyl transpeptidase, was used for the evaluation of NAFLD. Results A total of 53 participants with NAFLD (27 dapagliflozin; 26 pioglitazone) were included in this analysis. FLI decreased significantly in the dapagliflozin group (48.7 +/- 23.4 to 42.1 +/- 23.9) compared with the pioglitazone group (49.0 +/- 26.1 to 51.1 +/- 25.8; P < 0.01). Multiple linear regression analysis showed that the changes in FLI had a significantly positive correlation with changes in glycated hemoglobin (P = 0.03) and insulin level (P < 0.01) in the dapagliflozin group. Conclusion Dapagliflozin might be more beneficial than pioglitazone in patients with NAFLD. Improvements in FLI would be closely related to glycemic control.

引用

页码：1272 / 1277

页数：6

共 23 条

[1] Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD [J].